Crossmark

Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice

Crossref DOI link: https://doi.org/10.1007/s11060-025-04951-z

Published Online: 2025-02-11

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ong, Claire Victoria

Samlowski, Wolfram https://orcid.org/0000-0002-0713-914X
Funding

Funding for this research was provided by:

National Institutes of Health (CA035421)
License Information

Text and Data Mining valid from 2025-02-11

Version of Record valid from 2025-02-11
More Information

Article History

Received: 25 November 2024

Accepted: 23 January 2025

First Online: 11 February 2025

Declarations

:

: The design of this retrospective anonymized data analysis was reviewed by the Western IRB chair and was considered exempt from full IRB review.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below